KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Aquestive Therapeutics (AQST) EBIAT (2017 - 2025)

Aquestive Therapeutics has reported EBIAT over the past 9 years, most recently at -$31.9 million for Q4 2025.

  • Quarterly results put EBIAT at -$31.9 million for Q4 2025, down 86.81% from a year ago — trailing twelve months through Dec 2025 was -$83.8 million (down 89.83% YoY), and the annual figure for FY2025 was -$83.8 million, down 89.83%.
  • EBIAT for Q4 2025 was -$31.9 million at Aquestive Therapeutics, down from -$15.4 million in the prior quarter.
  • Over the last five years, EBIAT for AQST hit a ceiling of $8.1 million in Q1 2023 and a floor of -$31.9 million in Q4 2025.
  • Median EBIAT over the past 5 years was -$13.0 million (2022), compared with a mean of -$13.0 million.
  • Biggest five-year swings in EBIAT: skyrocketed 161.03% in 2023 and later tumbled 465.55% in 2024.
  • Aquestive Therapeutics' EBIAT stood at -$28.9 million in 2021, then surged by 57.33% to -$12.4 million in 2022, then surged by 34.33% to -$8.1 million in 2023, then plummeted by 110.27% to -$17.1 million in 2024, then plummeted by 86.81% to -$31.9 million in 2025.
  • The last three reported values for EBIAT were -$31.9 million (Q4 2025), -$15.4 million (Q3 2025), and -$13.5 million (Q2 2025) per Business Quant data.